Swedish Orphan Biovitrum ABCHIX:SOBIS 85 EV-to-FCF is 46.02 as of Jul. 08, 2026, which is 48% above its 10-year median of 31.09. GuruFocus rates CHIX:SOBIS with a GF Score™ of 85/100 and a GF Value™ of kr345.56 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 563 Drug Manufacturers companies, Swedish Orphan Biovitrum AB ranks worse than 71.23% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Swedish Orphan Biovitrum AB's Enterprise Value is kr184,064 Mil.
Swedish Orphan Biovitrum AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was kr4,000 Mil. Therefore, Swedish Orphan Biovitrum AB's EV-to-FCF for today is 46.02.
The historical rank and industry rank for Swedish Orphan Biovitrum AB's EV-to-FCF or its related term are showing as below:
CHIX:SOBIs'
s EV-to-FCF Range Over the Past 10 Years
Min: -253.22 Med: 31.09 Max: 821.59
Current: 45.95
During the past 13 years, the highest EV-to-FCF of Swedish Orphan Biovitrum AB was 821.59. The lowest was -253.22. And the median was 31.09.
CHIX:SOBIs's EV-to-FCF is ranked worse than 71.23% of 563
companies
in the Drug Manufacturers industry
Industry Median: 20.85
vs CHIX:SOBIs: 45.95
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Swedish Orphan Biovitrum AB (CHIX:SOBIs) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Swedish Orphan Biovitrum AB's PE Ratio (TTM) for today is calculated as:
Swedish Orphan Biovitrum AB's share price for today is kr463.20.
Swedish Orphan Biovitrum AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr2.540.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Swedish Orphan Biovitrum AB EV-to-FCF Related Terms
Swedish Orphan Biovitrum AB EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Swedish Orphan Biovitrum AB EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Swedish Orphan Biovitrum AB's EV-to-FCF falls into.
Swedish Orphan Biovitrum AB's current Enterprise Value is kr184,064 Mil.
Swedish Orphan Biovitrum AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr4,000 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Swedish Orphan Biovitrum AB (CHIX:SOBIS) has a EV-to-FCF of 46.02 as of Jul. 08, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Swedish Orphan Biovitrum AB and its competitors. This is 48% above median its historical median of 31.09. According to the industry distribution chart, Swedish Orphan Biovitrum AB ranks #401 out of 563 companies in the Drug Manufacturers industry, placing it in the top 71.2%.
Is Swedish Orphan Biovitrum AB's EV-to-FCF too high?
Swedish Orphan Biovitrum AB's current EV-to-FCF of 46.02 is 48% above median its 10-year median of 31.09. The Drug Manufacturers industry median EV-to-FCF is 20.85. Swedish Orphan Biovitrum AB's value of 46.02 is 120.7% above this industry median. Based on the distribution chart, Swedish Orphan Biovitrum AB ranks #401 out of 563 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 85/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Swedish Orphan Biovitrum AB ranks #401 out of 563 companies for EV-to-FCF. This places Swedish Orphan Biovitrum AB in the lower half of its industry. The industry median EV-to-FCF is 20.85. Swedish Orphan Biovitrum AB's value of 46.02 is 120.7% above this benchmark. While the company's 10-year median is 31.09 vs. the industry median of 20.85, Swedish Orphan Biovitrum AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.85, based on 563 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Swedish Orphan Biovitrum AB's current EV-to-FCF of 46.02 is 120.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Swedish Orphan Biovitrum AB and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Swedish Orphan Biovitrum AB's current EV-to-FCF is 46.02, which is 48% above median its own 10-year median of 31.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (CHIX:SOBIS) is currently considered Significantly Overvalued. The stock's GF Value™ is kr345.56, compared to a current price of kr463.20 — trading 34% above its estimated fair value. The current EV-to-FCF is 46.02, which is 48% above median its 10-year median of 31.09 and 120.7% above the Drug Manufacturers industry median of 20.85. Swedish Orphan Biovitrum AB's overall GF Score™ is 85/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (CHIX:SOBIS), the current EV-to-FCF is 46.02 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Swedish Orphan Biovitrum AB (CHIX:SOBIS) Overvalued in 2026?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued.
The current stock price of kr463.20 is trading 34% above its estimated GF Value™ of kr345.56.
GuruFocus considers Swedish Orphan Biovitrum AB to be Significantly Overvalued.
Key valuation signals for CHIX:SOBIS:
EV-to-FCF: 46.02 (48% above median its 10-year median of 31.09)
GF Value™: kr345.56 vs. price of kr463.20 (34% above fair value)
Industry Position: 120.7% above the Drug Manufacturers median (#401 of 563)
No single metric tells the full story. See the CHIX:SOBIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
85GF Score
Get the complete analysis for CHIX:SOBIS
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:SOBIS has been successfully added to your 
